Literature DB >> 11582530

[Thyroglossal duct cysts in paediatric patients: early operative intervention reduces rate of complications].

S von Bismarck1, M E Höllwarth.   

Abstract

BACKGROUND: Thyroglossal duct cysts arise from mucus production in an incomplete regressed thyroglossal duct. Often they are only noticed in case of infection or secondary fistulation. The operative management is a Sistrunk procedure. METHOD AND PATIENTS: In a retrospective study we analyse 26 patients aged 0,3 - 10 years with histological confirmed thyroglossal duct cysts, 13 of these (50 %) had signs of infection. In 15 patients the cyst was primarily cored out, in 11 patients the core out followed a primarily incision and drainage.
RESULTS: 5 patients (19 %) developed recurrent cysts. Patients with signs of infection or incomplete resection of hyoid bone had a high risk of developing recurrence.
CONCLUSIONS: We propose an early operative treatment for thyroglossal duct cysts with a complete Sistrunk procedure.

Entities:  

Mesh:

Year:  2001        PMID: 11582530     DOI: 10.1055/s-2001-17223

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  4 in total

Review 1.  [Sclerotherapy for cystic lesions of the head and neck region].

Authors:  S Knipping; G Goetze
Journal:  HNO       Date:  2008-03       Impact factor: 1.284

2.  Thyroglossal duct cysts: 20 years' experience (1992-2011).

Authors:  Julie de Tristan; Johannes Zenk; Julian Künzel; Georgios Psychogios; Heinrich Iro
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-08-19       Impact factor: 2.503

3.  Thyroglossal duct cyst's inflammation. When do we operate?

Authors:  Ch Kaselas; G Tsikopoulos; Ch Chortis; B Kaselas
Journal:  Pediatr Surg Int       Date:  2005-11-01       Impact factor: 1.827

4.  Large thyroglossal duct cyst of the neck mimicking cervical cystic lymphangioma in a neonate: a case report.

Authors:  Ning Fang; Laina Ndapewa Angula; Yu Cui; Xin Wang
Journal:  J Int Med Res       Date:  2021-04       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.